NASDAQ:HGSI Human Genome Sciences (HGSI) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free HGSI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Human Genome Sciences alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Human Genome Sciences Stock (NASDAQ:HGSI)Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. The Company’s products include BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax. HGS continues to deliver raxibacumab to the United States Strategic National Stockpile (SNS) for emergency use in treating inhalation anthrax. In addition to the Company’s internal pipeline, it has financial rights to two drugs that GlaxoSmithKline (GSK) has advanced to late-stage development. These include darapladib and albiglutide. A randomized Phase 2 trial is evaluating mapatumumab in combination with Nexavar (sorafenib) for the treatment of advanced hepatocellular cancer. The Company manufactures multiple protein and antibody drugs for use in research, clinical and commercial activities. It produces and purifies these protein and antibody drugs in three process development and manufacturing facilities. In August 2012, GlaxoSmithKline plc acquired HGS.Read More Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. HGSI Stock News HeadlinesApril 1, 2024 | msn.comResearchers explore the hagfish genome, reconstruct the early genomic history of vertebratesFebruary 29, 2024 | msn.comBecoming human: An ancient genome perspectiveApril 26, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.February 27, 2024 | msn.comInnovative computational tools provide new insights into the polyploid wheat genomeJanuary 30, 2024 | msn.comThe roles of genes and 3D genome folds in determining healthJanuary 17, 2024 | msn.comUSC Scientists Discover Protein Key to 3D Genome Control and Gene SilencingJanuary 15, 2024 | msn.comNew research reveals major difference in genomes of American and Chinese chestnutDecember 8, 2023 | msn.comGroundbreaking 'Gnocchi' map reveals hidden secrets of the human genomeApril 26, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.October 19, 2023 | msn.comLabour urged to protect UK’s genetic sciences from hostile foreign statesSeptember 6, 2023 | forbes.comCelera's About-FaceAugust 9, 2023 | msn.comThe Next Human Genome ChallengeJuly 19, 2023 | finanznachrichten.deAutolus Therapeutics plc: Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial OfficerJuly 19, 2023 | stockhouse.comAutolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial OfficerMay 30, 2023 | thestreet.comHuman Genome Hit by Benlysta Sales WorryMay 14, 2023 | msn.comThe Science Of Health: How The New Reference Genome Will Help Understand Link Between Human Genes And HealthMay 11, 2023 | msn.comThe Human Genome: Global DNA data gets diversity bumpMay 11, 2023 | msn.comScientists reveal more inclusive update to human genomeMay 10, 2023 | msn.comScientists have updated the human genome to make it more equitable and inclusiveMay 2, 2023 | washingtonpost.comA genome project cracks mysteries of evolution — and Balto the superdogApril 24, 2023 | msn.comCanadian science pioneers’ role in the Human Genome Project shows why it’s crucial to fund researchApril 13, 2023 | msn.comThe human genome: The most important map ever producedMarch 30, 2023 | msn.comLocal Press: UAE's genome project will benefit the entire Arab worldMarch 8, 2023 | msn.comHuman genome editing offers tantalizing possibilities – but without clear guidelines, many ethical questions still remainMarch 3, 2023 | yahoo.comAsia’s richest man to enter genetic testing market with $145 kitsFebruary 17, 2023 | bbc.co.ukThe human genomeFebruary 16, 2023 | bbc.comWhy the human genome was never completedSee More Headlines Receive HGSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Human Genome Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:HGSI CUSIPN/A CIK901219 Webwww.hgsi.com Phone+1-301-3098504FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report HGSI Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Human Genome Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Human Genome Sciences investors own include Bank of America (BAC), CEMEX (CX), Cisco Systems (CSCO), Citigroup (C), Beazer Homes USA (BZH), BlackBerry (BB), Advanced Micro Devices (AMD), Alio Gold (ALO), Allot Communications (ALLT) and Altaba (AABA). This page (NASDAQ:HGSI) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Human Genome Sciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
